TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Teplizumab for Prevention of Type 1 Diabetes In Relatives At-Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between ages of 8-45 years~* Have a relative with type 1 diabetes~* If first degree relative must be 8-45 years old (brother, sister, parent, offspring)~* If second degree relative must be between 8-20 years old (niece, nephew, aunt, uncle, grandchild, cousin)~* Abnormal glucose tolerance by OGTT confirmed with 7 weeks of baseline visit \[fasting blood glucose greater than 110mg/dL or and less than 126 mg/dL OR 2 hour glucose greater or equal to 140 mg/dL and less than 200 mg/dL OR 30, 60, or 90 minute value on OGTT greater than or equal to 200 mg/dL\]~* Presence of at least two confirmed diabetes autoantibodies~Exclusion Criteria:~* type 1 diabetes previously diagnosed or detected at screening \[fasting glucose greater or equal to 126 mg/dL or 2 hour glucose greater or equal to 200 mg/dL\]~* abnormalities in blood counts, liver enzymes, international normalised ratio (INR),~* positive purified protein derivative (PPD) test~  * vaccination with live virus within 6 weeks of randomization~* evidence of acute infection based on laboratory testing or clinical evidence~* serological evidence of past current or past HIV , hepatitis B, or hepatitis C infection~* Be currently pregnant or lactating~* Prior treatment with study drug~* Prior treatment with other monoclonal antibody in past one year

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- teplizumab (Type: ACTIVE_COMPARATOR): Intravenous infusions of teplizumab given for 14 consecutive days. Each infusion takes about 30 minutes and is followed by a 2 hour observation period.
- Placebo infusion (Type: PLACEBO_COMPARATOR): Intravenous infusion of placebo (saline) will be given for 14 consecutive days. Infusions will take approximately 30 minutes and will be followed by a two hour observation period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of systemic lupus erythematosus for at least 6 months.~* Documentation of at least one of the following: ANA titer \>= 1:160 or positive anti-dsDNA antibodies.~* Stable systemic lupus erythematosus medication regimen.~* Other than systemic lupus erythematosus, subject should be in general good health.~Exclusion Criteria:~* Male.~* Drug-induced or highly active systemic lupus erythematosus.~* Significant autoimmune disease other than lupus.~* Significant, uncontrolled or unstable disease in any organ.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Single Dose (Type: EXPERIMENTAL): Subjects enrolled in the Single Ascending Dose (SAD) part of the study will receive a single dose of study drug or placebo. (Groups 1, 2, 3, 4, 5 and 6).
- Multiple Dose (Type: EXPERIMENTAL): Subjects enrolled in the Multiple Ascending Dose (MAD) part of the study will receive multiple doses of study drug or placebo. (Groups 7, 8, 9, 10 and 11)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Healthy adults who completed the primary immunization in study IC51 309~* Male and female healthy subjects aged at least 18 years with written informed consent and either no childbearing potential or negative pregnancy test~Main Exclusion Criteria:~• History of immunodeficiency or immunosuppressive therapy, known Human Immunodeficiency Virus (HIV), or drug addiction including alcohol dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese children with Noonan syndrome clinically diagnosed in one of the following ways: 1. Clinically diagnosed by at least two medical experts using van der Burgt score list, 2. Clinically diagnosed by one medical expert using van der Burgt score list and diagnosed by result of genetic testing for Noonan syndrome, 3. Clinically diagnosed by one medical expert using van der Burgt score list and diagnosed by the same medical expert based on the results of centralised evaluation of facial change using van der Burgt score list~* Height SDS (standard deviation score): -2 SDS or below (according to the Japanese reference data)~* Age: boys 3 to below 11 years, girls 3 to below 10 years~* Height records must be available within the period between 40 and 64 weeks prior to Visit 1 (screening)~* Prepubertal children (definition for girls breast and pubes of Tanner stage is I, and none of menses, and for boys testicular volume below 4 mL, and pubes and penis of Tanner stage is I)~Exclusion Criteria:~* Children with known or suspected hypersensitivity against human growth hormone (hGH) or related products (including any components of the trial products)~* Children with diabetic type diagnosed with the Japanese Diabetes Society Classification~* Children with history or presence of active malignancy~* Children who have received GH (growth hormone) treatment~* Children who have received systemic administration of the following medications within two years prior to Visit 1 (screening): Thyroid hormone (except replacement therapy), antithyroid hormone, androgen, oestrogen, progesterone, anabolic steroid, adrenocortical steroid treatment period for at least 13 weeks), derivative of gonadotropin releasing hormone and somatomedin C (IGF-I)

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- 0.033 mg/kg/day (Type: EXPERIMENTAL): None
- 0.066 mg/kg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained and signed. Age 18-60 years. ECOG performance status (PS) 0-2. Histologically confirmed CD20-positive DLBCL, any stage, bulky or nonbulky disease.~* No prior treatment for lymphoma. Willing to have documentation of HIV status. CD4 count ≥ 100 cells/µL if HIV-infected. Measurable disease by physical exam.~* Adequate bone marrow renal and hepatic function as evidenced by the following:~  * Absolute neutrophil count (ANC) ≥ 1,000/µL~ * Platelet count ≥ 100,000/µL~ * Creatinine ≤ 1.5 mg/dL~ * Total bilirubin ≤ 2 mg/dL (unless directly attributable to lymphoma)~* Able to understand and comply with protocol requirements for the entire length of the study.~* Willing to reside \<50 kilometers from Kamuzu Central Hospital (KCH) until chemotherapy completion.~* Negative urine B-HCG in women of child-bearing potential within 7 days prior to start of treatment.~* Fertile patients must use effective contraception (condom or other barrier methods, oral contraceptives, implantable contraceptives, intrauterine devices) during and for six months after completion of treatment.~Exclusion Criteria~* Pregnant or nursing. Central nervous system (CNS) involvement by lymphoma (clinically or cytologically confirmed).~* Receiving other anti-cancer or investigational therapy during study treatment, apart from those agents specified in the study protocol.~* Known cardiac disease including any of the following:~  * New York Heart Association (NYHA) Grade II or greater congestive heart failure~ * History of myocardial infarction or unstable angina within 6 months prior to Day 1~ * History of stroke or transient ischemic attack within 6 months prior to Day 1~* Second active malignancy requiring systemic therapy.~* Hepatitis B virus (HBV) surface-antigen positive unless receiving both tenofovir and lamivudine as part of antiretroviral therapy if HIV-infected.~* Other serious, ongoing, non-malignant disease or infection that would in the opinion of the site investigator compromise other protocol objectives.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- R-CHOP (Type: EXPERIMENTAL): We will enroll 40 adult patients age 18-60 years (20 HIV-infected with CD4 count ≥ 100 cells/µL, 20 HIV-uninfected) who will receive a maximum of 6-8 cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) over 18-24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (≥ 18 years) patients with chronic hepatitis C and detectable HCV RNA by Polymerase Chain Reaction (PCR) after completion of previous direct-acting antiviral regimen, and eligible for antiviral treatment.~Exclusion Criteria:~* Patients with decompensated cirrhosis (Child-Pugh score B and C).~* Patients with platelet count less than 50000/ mm³.~* Patients with HCC or extrahepatic malignancy.~* Pregnancy or inability to use an effective contraceptive method.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A: SOF/VEL/VOX with RBV (Type: EXPERIMENTAL): Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily) plus Ribavirin (weight-based dose 1000 or 1200 mg daily according to patient body weight: \< or \> 60 kg).~Another name: Vosevi, RBV
- Group B: SOF/VEL/VOX (Type: ACTIVE_COMPARATOR): Drug: Sofosbuvir/Velpatasvir/Voxilaprevir 400/100/100 mg tablets (single pill combination administered orally once daily).~Another name: Vosevi

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Sign an Institutional Review Board (IRB)-approved informed consent document.~2. Age \>/= than18 years~3. de novo or secondary International Prostate Symptom Score (IPSS) low- or intermediate-1 - risk MDS, including CMML~4. Eastern Cooperative Oncology Group (ECOG) performance status of \</= 3 at study entry.~5. Organ function as defined: Serum creatinine \</= 3 x Upper Limit of Normal (ULN), Total bilirubin \</= 2 x ULN, Alanine transaminase (ALT) (SGPT) \</= 2 x ULN~6. Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days and will also need to use contraceptives. Men must agree not to father a child and agree to use a condom if his partner is of child bearing potential.~Exclusion Criteria:~1. Breast feeding females~2. Prior therapy with decitabine or azacitidine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): Patients randomized to receive Decitabine 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
- Azacitidine (Type: EXPERIMENTAL): Patients randomized to receive Azacitidine 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has entered the Maintenance Phase of the double-blind trial, SP902, (ie, has taken at least 1 dose of SP902 Maintenance Phase trial medication) and either completed SP902 or met an exit criterion in SP902; subject is allowed up to 2 concomitant Antiepileptic Drugs (AEDs)~Exclusion Criteria:~* Subject meets the withdrawal criteria (excluding exit criteria) for the SP902 trial, or is experiencing an ongoing Serious Adverse Event (SAE)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Lacosamide (Type: EXPERIMENTAL): Lacosamide tablets for dosing 100 -800 mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetic Study in Hepatocellular Carcinoma Patients.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Eligible patients should fulfill the following criteria:~  1. A diagnosed HCC patient.~ 2. Age ≥20 years.~ 3. Patients with adequate organ function.~ 4. HCC not eligible for curative measures (radiofrequency, microwave and surgery).~Exclusion Criteria:~* Patient will be excluded for any of the following:~  1. Patients refused to sign the written consent.~ 2. Age \> 75 years.~ 3. The presence of major portal vein thrombosis.~ 4. Extrahepatic metastases.~ 5. Hepatic encephalopathy.~ 6. Current infection.~ 7. Gastrointestinal bleeding within a month.~ 8. Uncontrolled ascites.~ 9. Serum bilirubin \> 3.0 mg/dl, serum albumin \< 2.8 g/dl, serum creatinine concentration \> 1.5 mg/dl, white blood cell counts \< 3,000/mm3 and platelet counts \< 30,000/mm3.~ 10. Patients with other types of malignancy, advanced organ failure, and advanced medical co-morbidity.~ 11. Pregnant females.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: None

Study Arms:
- HCC patients (Type: None): 116 hepatocellular carcinoma patients underwent TACE

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The study disease was diagnosed on the basis of clinical criteria: Nasal symptoms (presence of nasal blockage, sneezing, nasal itching and rhinorrhea) and non-nasal symptoms (ocular itching, lacrimation, itching of ears and/or palate and ocular redness), as well as the skin prick test performed at the time of selection or within the year prior to entering.~* Patients with history of Seasonal Allergic Rhinitis, positive skin prick test and symptoms were included if they were between 12 and 70 years old, gave their informed consent, attended the required visits scheduled and also underwent a complete medical examination..~Exclusion Criteria:~* Patients were excluded if they had a significant nasal abnormality which could interfere with the aim of the study, acute or chronic sinusitis, asthma or any condition, disease or hypersensitivity that could be harmed.~* Patients were not allowed to take forbidden medications or not comply the study requirements.~* Patients who were currently participating in or had participated in another clinical trial within the previous three months or were planning to travel outside of the study area during the course of the study were excluded.~* Pregnant or breast-feeding women were also excluded.~* Women of childbearing potential had a pregnancy test done

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Bilastine (Type: EXPERIMENTAL): None
- Desloratadine (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of MT-1303

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* RRMS as defined by the revised McDonald criteria~* Evidence of recent MS activity defined as either:~  * at least one documented relapse in the previous 12 months, OR~ * a positive gadolinium (Gd)-enhanced MRI scan within 3 months prior to screening, OR~ * at least two documented relapses in the previous 24 months with a positive Gd-enhanced MRI scan within the previous 12 months~* Expanded Disability Status Score (EDSS) score ≥0.0 and ≤5.5 points.~Exclusion Criteria:~* Primary progressive, secondary progressive or progressive relapsing MS at screening~* Disease duration \>15 years combined with an EDSS score ≤2.0~* Relapse of MS during the Screening Period~* History or known presence of other neurological disorders likely to render the subject unsuitable for the study~* History of any of a list of pre-defined cardiovascular diseases~* History or known presence of any significant central nervous system, infectious, metabolic, oncological, ophthalmological or respiratory system disease or illness likely to render the subject unsuitable for the study~* Previous exposure to any sphingosine 1-phosphate receptor modulator~* Receipt of a live vaccine or systemic corticosteroid use within 28 days prior to randomisation~* Previous treatment with beta-interferons or glatiramer acetate within 14 days prior to randomisation~* Previous treatment with intravenous immunoglobulin, plasmapheresis, certain immunosuppressants, lymphocyte-depleting therapy, total body irradiation or bone marrow transplantation~* Need, or likely need for, treatment with Class I or III anti-arrhythmic drugs or with heart-rate-lowering beta-blockers or calcium-channel blockers, or with any other drugs which can reduce the heart rate~* Evidence of significant anaemia, thrombocytopenia, leucopoenia or lymphocytopenia, renal or hepatic impairment~* Clinically significant electrocardiogram (ECG) findings.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- MT-1303-Low (Type: EXPERIMENTAL): MT-1303-Low Dose
- MT-1303-Middle (Type: EXPERIMENTAL): MT-1303-Middle Dose
- MT-1303-High (Type: EXPERIMENTAL): MT-1303-High Dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Biologicals in Treatment of Severe Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* asthma that remains uncontrolled despite moderate to high dose inhaled corticosteroid and additional therapy with at least one other controller medication and need for continuous per oral corticosteroids (OCS) or contraindications (or clinically significant side effects of OCS) against OCS and/or frequent courses (two or more per year) of OCS~Exclusion Criteria:~* patients without asthma

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- anti-IL5/IL5R-therapy group (Type: None): Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IL5/IL5R
- anti-IgE-therapy group (Type: None): Asthma patients, asthma and rhinitis, asthma and nasal polyps and anti-IgE-therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete